Methods and compositions for determining altered susceptibility of HIV-1 to anti-HIV drugs

US8637252B2 · kind B2 · utility

Assignee

• Monogram Biosciences, Inc. · US

Inventors

• Soumi Gupta · San Francisco, US
• Signe Fransen · San Francisco, US
• Ellen Paxinos · San Jose, US
• Neil T. Parkin · Belmont, US

Key dates

• Filing date: Nov 15, 2011
• Grant date: Jan 28, 2014
• Expiry date: Nov 15, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/156
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

This invention relates, in part, to methods and compositions for determining altered susceptibility of a human immunodeficiency virus (“HIV”) to the non-nucleoside reverse transcriptase inhibitors (“NNRTIs”) efavirenz (“EFV”), nevirapine (“NVP”), and delavirdine (“DLV”), the nucleoside reverse transcriptase inhibitor AZT, and the integrase strand transfer inhibitors diketo acid 1, diketo acid 2, and L-870,810 by detecting the presence of a mutation or combinations of mutations in the gene encoding HIV reverse transcriptase that are associated with altered susceptibility to the anti-HIV drugs.